[Retracted] The Clinical Efficacy and Economic Benefits of Recombinant Human Thrombopoietin for the Treatment of Chemotherapy or Chemoradiotherapy-Induced Thrombocytopenia
Table 5
Comparison of indicators in the use of rhTPO for treatment of grade III and IV thrombocytopenia [n, (%)].
Indicators
Use of recombinant human thrombopoietin (rhTPO)
Z/χ2 value
P Value
Grade III (n = 94)
Grade IV (n = 39)
Days of treatment
6.00 (4.00, 8.00)
6.00 (4.00, 11.00)
−0.761
0.447
Time to increase platelets (days)
5.50 (3.00, 8.00)
6.00 (3.00, 11.00)
−1.023
0.306
Delay of the next chemoradiotherapy cycle (days)
3.00 (0, 9.25)
3.00 (0, 8.00)
−0.094
0.925
Prolonged hospitalization due to platelet decline (days)
3.50 (0, 7.00)
5.00 (0, 8.00)
−1.304
0.192
Increased hospitalization costs due to platelet decline
